Akari Therapeutics Plc SEC filings AKTX
Akari Therapeutics Plc has 743 filings in SEC EDGAR's recent list, going back to Apr 13, 2012. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Oct 1, 2026 | Oct 1, 2026 |
| DEF 14A | Proxy statement | Jun 4, 2026 | Jun 4, 2026 |
| PRE 14A | Preliminary proxy statement | May 22, 2026 | May 22, 2026 |
| DEF 14A | Proxy statement | Feb 2, 2026 | Feb 2, 2026 |
| PRE 14A | Preliminary proxy statement | Jan 22, 2026 | Jan 22, 2026 |
| DEF 14A | Proxy statement | Nov 17, 2025 | Nov 17, 2025 |
| PRE 14A | Preliminary proxy statement | Nov 7, 2025 | Nov 7, 2025 |
| DEF 14A | Proxy statement | Jun 6, 2025 | Jun 6, 2025 |
| PRE 14A | Preliminary proxy statement | May 23, 2025 | May 23, 2025 |
| DEF 14A | Proxy statement | Jun 3, 2024 | Jun 27, 2024 |
| DEFA14A | Additional proxy material | May 18, 2016 | — |
| DEF 14A | Proxy statement | Apr 28, 2016 | Jun 29, 2016 |
| DEFA14A | Additional proxy material | Sep 9, 2015 | — |
| DEFA14A | Additional proxy material | Aug 18, 2015 | — |
| DEFA14A | Additional proxy material | Aug 18, 2015 | — |
| DEFA14A | Additional proxy material | Aug 13, 2015 | — |
| DEFM14A | Defm 14a | Aug 3, 2015 | — |
| DEFA14A | Additional proxy material | Jul 15, 2015 | — |
| PREM14A | Filing | Jul 15, 2015 | Jul 14, 2015 |
| DEFA14A | Additional proxy material | Jul 13, 2015 | — |
| DEFA14A | Additional proxy material | Jun 29, 2015 | — |
| DEFA14A | Additional proxy material | Jun 26, 2015 | — |
| DEFA14A | Additional proxy material | Jun 24, 2015 | — |
| DEFA14A | Additional proxy material | May 29, 2015 | — |
| DEF 14A | Proxy statement | May 28, 2015 | Jun 29, 2015 |
Showing 25 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AKTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Tampa, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1541157
- Former names
- Celsus Therapeutics Plc. (until Sep 15, 2015); Morria Biopharmaceuticals PLC (until Jun 20, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.